Brise Pharmaceuticals Raises Nearly $20M In Series Pre-A And Pre-A+ Financing

SHANGHAI, April 22, 2024 /PRNewswire/ -- Brise Pharmaceuticals Co., LTD. (Brise), a pioneering company specializing in innovative treatments for acute and chronic pain, has recently completed Pre-A and Pre-A+ financing with a total of approximately $20 million. This Pre-A round is led by Shunxi Fund, followed by Cnfuel Capital, Vinner Therapeutics and existing investors such as Qiming Venture Partners and BioTrack Capital. The Pre-A+ round is exclusively invested by Sherpa Healthcare Partners.

Brise has advanced two molecules to the clinical stage in US and China. The funds raised will be used to advance the company's product pipeline in the preclinical and clinical stages, as well as to further refine and validate the Trigeminovascular System (TVS) biology-based drug development platform and the Dorsal Root Ganglion (DRG) biology-based drug development platform.

Brise, led by CEO Dr. Guochun Li, stands as a clinical-stage biopharmaceutical company with a singular focus on the development of innovative and highly differentiated analgesic treatments for debilitating pain conditions with large unmet needs, placing a particular emphasis on addressing migraine, neuropathic and musculoskeletal pain. The organization's vision is to provide safe, effective, and accessible pain relief solutions for the multitude of patients worldwide grappling with poorly managed pain conditions.

View original content:https://www.prnewswire.com/news-releases/brise-pharmaceuticals-raises-nearly-20m-in-series-pre-a-and-pre-a-financing-302123069.html

SOURCE Brise Pharmaceuticals Co., Ltd

First published on Tue, Apr 23, 2024

Enjoyed what you've read so far? Great news - there's more to explore!

Stay up to date with the latest news, a vast collection of tech articles including introductory guides, product reviews, trends and more, thought-provoking interviews, hottest AI blogs and entertaining tech memes.

Plus, get access to branded insights such as informative white papers, intriguing case studies, in-depth reports, enlightening videos and exciting events and webinars from industry-leading global brands.

Dive into TechDogs' treasure trove today and Know Your World of technology!

Disclaimer - Reference to any specific product, software or entity does not constitute an endorsement or recommendation by TechDogs nor should any data or content published be relied upon. The views expressed by TechDogs' members and guests are their own and their appearance on our site does not imply an endorsement of them or any entity they represent. Views and opinions expressed by TechDogs' Authors are those of the Authors and do not necessarily reflect the view of TechDogs or any of its officials. While we aim to provide valuable and helpful information, some content on TechDogs' site may not have been thoroughly reviewed for every detail or aspect. We encourage users to verify any information independently where necessary.

Tags:

Brise Pharmaceuticals Co. Ltd BioTrack Capital Cnfuel Capital Trigeminovascular System Dorsal Root Ganglion

Join The Discussion

- Promoted By TechDogs -

Pharmaceutical Technology